POLO Trial Shows Maintenance Olaparib Improves PFS in Metastatic Pancreatic Cancer - The ASCO Post
PARP inhibitors in pancreatic cancer: molecular mechanisms and clinical applications | Molecular Cancer | Full Text
Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer | NEJM
Pancreatic Cancer - ASCO GI 2021 Highlights - Module - 2021 ASCO GI - Oncology - Clinical Care Options
Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer | NEJM
FacingOurRisk on Twitter: "POLO: a study for pple w/pancreatic cancer & BRCA mutation olaparib (a PARP inhibitor) as maintenance therapy. https://t.co/ud1DOTbQJJ https://t.co/1s6t8fkFVH" / Twitter
Asco 2019 – Polo reveals an overall survival hole | Evaluate
Efficacy – LYNPARZA® (olaparib)
Treatment Paradigm – LYNPARZA® (olaparib)
Dr. Antonio Calles 🫁🚭 on Twitter: "LBA4 POLO trial: olaparib maintenance in germline BRCA mutant pancreatic adenocarcinoma. Nice data but... PFS as primary endpoint comparing active drug vs no treatment is not
Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer
Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer | NEJM
Efficacy – LYNPARZA® (olaparib)
Olaparib maintenance therapy improves PFS in BRCA-mutated metastatic pancreatic cancer | Latest news for Doctors, Nurses and Pharmacists | Pharmacy
Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer | NEJM
Olaparib maintenance therapy improves PFS in BRCA-mutated metastatic pancreatic cancer | Latest news for Doctors, Nurses and Pharmacists | Pharmacy
Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer | NEJM
Cureus | Poly Adenosine Diphosphate-Ribose Polymerase (PARP) Inhibitors in Pancreatic Cancer
Health-related quality of life in patients with a germline BRCA mutation and metastatic pancreatic cancer receiving maintenance olaparib - Annals of Oncology
Pancreatic Cancer - ASCO GI 2021 Highlights - Module - 2021 ASCO GI - Oncology - Clinical Care Options
5697_O REILLY Transcript.indd
Olaparib in Pancreas Cancer | Polo Trial | One oncologist breaks it down - YouTube
Predicting Benefit From Olaparib Maintenance in Metastatic Pancreatic Cancer: The POLO Trial - Cancer Therapy Advisor
